Researchers have found that 1 in 5 adults with hypertension now have multiple cardiometabolic risk factors, driven largely by rising diabetes rates.
Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback